1. Home
  2. IMMX vs SPTX Comparison

IMMX vs SPTX Comparison

Compare IMMX & SPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immix Biopharma Inc.

IMMX

Immix Biopharma Inc.

N/A

Current Price

$7.92

Market Cap

784.8M

Sector

Health Care

ML Signal

N/A

Logo Seaport Therapeutics Inc. Common Stock

SPTX

Seaport Therapeutics Inc. Common Stock

N/A

Current Price

$20.00

Market Cap

929.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IMMX
SPTX
Founded
2014
2024
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
784.8M
929.8M
IPO Year
2021
2026

Fundamental Metrics

Financial Performance
Metric
IMMX
SPTX
Price
$7.92
$20.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
9
Target Price
$24.05
★ $37.13
AVG Volume (30 Days)
★ 1.2M
235.0K
Earning Date
11-12-2026
11-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.78
$15.79
52 Week High
$15.10
$28.38

Technical Indicators

Market Signals
Indicator
IMMX
SPTX
Relative Strength Index (RSI) 42.67 48.16
Support Level $7.82 $18.79
Resistance Level $9.04 $22.53
Average True Range (ATR) 0.62 1.46
MACD 0.16 0.03
Stochastic Oscillator 41.81 29.08

Price Performance

Historical Comparison
IMMX
SPTX

About IMMX Immix Biopharma Inc.

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

About SPTX Seaport Therapeutics Inc. Common Stock

Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.

Share on Social Networks: